Core Insights - Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart, showing promising safety and efficacy in preventing organ rejection in kidney transplant patients [1][2][3] Group 1: Clinical Trial Results - The overall mean estimated glomerular filtration rate (eGFR) after day 30 post-transplant was reported at 70.5 mL/min/1.73m², with mean eGFR above 60 mL/min/1.73m² at all reported time points [1][2] - Historical studies indicate that standard calcineurin inhibitor-based immunosuppression typically results in mean eGFRs of approximately 50 mL/min/1.73m² during the first year post-transplant, while tegoprubart showed mean eGFRs above 90 mL/min/1.73m² in two participants after one year [2][3] Group 2: Safety Profile - Tegoprubart demonstrated a generally safe and well-tolerated profile, with no cases of hyperglycemia, new onset diabetes, or tremor reported, which are common side effects of standard immunosuppression therapies [3] - Three subjects discontinued the study due to hair loss and fatigue, viral infection, and rejection, but there were no cases of graft loss or death [3] Group 3: Future Developments - Eledon is conducting a Phase 1b trial, a Phase 2 trial (BESTOW), and a long-term safety and efficacy extension study to further evaluate tegoprubart for kidney transplant patients [4][5] - The company anticipates completing enrollment in the Phase 2 BESTOW trial by the end of the year [2]
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation